 This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered as a 144-hour continuous intravenous IV infusion as a monotherapy or in combination with gemcitabine in advanced pancreatic cancer patients as 2nd 3rd line therapy. 